Efficacy and safety of progressively reducing biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in persistent remission: a study protocol for a non-inferiority randomized, controlled, single-blind trial

Peer Review reports

Original Submission
1 Sep 2021	Submitted	Original manuscript
17 Feb 2022	Reviewed	Reviewer Report - Sanaz Bemani
30 Mar 2022	Reviewed	Reviewer Report - Lamis Kaddam
8 Jun 2022	Author responded	Author comments - Shangwen Lei
Resubmission - Version 2
8 Jun 2022	Submitted	Manuscript version 2
5 Jul 2022	Reviewed	Reviewer Report - Alexander Gough
12 Jul 2022	Author responded	Author comments - Shangwen Lei
Resubmission - Version 3
12 Jul 2022	Submitted	Manuscript version 3
Publishing
13 Jul 2022	Editorially accepted
27 Jul 2022	Article published	10.1186/s13063-022-06543-y

Back to article page